Shinpoong Pharmaceutical (019170) Fundamentals 2026 — P/E 37.9x, Revenue Analysis | SniperIQ
Shinpoong Pharmaceutical (019170) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩393.5B, trading at ₩7610.00 on the KSC. This SniperIQ fundamentals page covers Shinpoong Pharmaceutical's valuation (P/E 37.9x, P/B 1.4x), profitability (net margin 4.5%), revenue (₩234.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shinpoong Pharmaceutical's market cap?
Shinpoong Pharmaceutical (019170) has a market capitalization of approximately ₩393.5B, trading at ₩7610.00 on the KSC. Market cap moves with the live share price.
What is Shinpoong Pharmaceutical's P/E ratio?
Shinpoong Pharmaceutical's trailing twelve-month P/E ratio is 37.9x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shinpoong Pharmaceutical?
Shinpoong Pharmaceutical runs a net profit margin of 4.5%, a gross margin of 43.6%, and an operating margin of 6.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shinpoong Pharmaceutical generate?
Shinpoong Pharmaceutical reported revenue of ₩234.7B for fiscal year 2025, with net income of ₩8.8B and earnings per share (EPS) of 172. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shinpoong Pharmaceutical pay a dividend?
Shinpoong Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Shinpoong Pharmaceutical financially healthy?
Shinpoong Pharmaceutical carries a debt-to-equity ratio of 0.19x and a current ratio of 3.20x, with a market beta of 1.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shinpoong Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shinpoong Pharmaceutical (019170) the key facts are: market cap ₩393.5B, P/E 37.9x, revenue ₩234.7B, 52-week range 7560-15900. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shinpoong Pharmaceutical's full fundamentals live
Get Shinpoong Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.